170 related articles for article (PubMed ID: 28967825)
1. Evaluation of drug content (potency) for compounded and FDA-approved formulations of doxycycline on receipt and after 21 days of storage.
KuKanich K; KuKanich B; Slead T; Warner M
J Am Vet Med Assoc; 2017 Oct; 251(7):835-842. PubMed ID: 28967825
[TBL] [Abstract][Full Text] [Related]
2. Doxycycline concentration over time after storage in a compounded veterinary preparation.
Papich MG; Davidson GS; Fortier LA
J Am Vet Med Assoc; 2013 Jun; 242(12):1674-8. PubMed ID: 23725430
[TBL] [Abstract][Full Text] [Related]
3. Analysis of lomustine drug content in FDA-approved and compounded lomustine capsules.
KuKanich B; Warner M; Hahn K
J Am Vet Med Assoc; 2017 Feb; 250(3):322-326. PubMed ID: 28117638
[TBL] [Abstract][Full Text] [Related]
4. Variable accuracy, precision, and consistency of compounded famciclovir formulated for management of feline herpesvirus-1 in cats.
O'Leary LM; Allbaugh RA; Schrunk DE; Olsen TE; Sebbag L
Vet Ophthalmol; 2021 Nov; 24(6):627-638. PubMed ID: 34117694
[TBL] [Abstract][Full Text] [Related]
5. Long-term Stability of a Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration.
Adin D; Johnson PR; Kim CH; Nguyenba T; Rosen S
J Vet Intern Med; 2017 Nov; 31(6):1822-1826. PubMed ID: 28913839
[TBL] [Abstract][Full Text] [Related]
6. Quality assessment of fluconazole capsules and oral suspensions compounded by pharmacies located in the United States.
Laporte CM; Cruz-Espindola C; Thungrat K; Schick AE; Lewis TP; Boothe DM
Am J Vet Res; 2017 Apr; 78(4):421-432. PubMed ID: 28346002
[TBL] [Abstract][Full Text] [Related]
7. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
Strauch S; Jantratid E; Dressman JB
J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
[TBL] [Abstract][Full Text] [Related]
8. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
[TBL] [Abstract][Full Text] [Related]
9. Stability of an extemporaneously compounded baclofen oral liquid.
Johnson CE; Hart SM
Am J Hosp Pharm; 1993 Nov; 50(11):2353-5. PubMed ID: 8266961
[TBL] [Abstract][Full Text] [Related]
10. Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry.
Ciavarella AB; Khan MA; Gupta A; Faustino PJ
PDA J Pharm Sci Technol; 2016 11/12; 70(6):523-532. PubMed ID: 27974592
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date.
Peacock GF; Sauvageot J; Hill A; Killian A
Int J Pharm Compd; 2016; 20(1):81-5. PubMed ID: 27125058
[TBL] [Abstract][Full Text] [Related]
12. The stability of quetiapine oral suspension compounded from commercially available tablets.
Tran J; Gervase MA; Evans J; Deville R; Dong X
PLoS One; 2021; 16(8):e0255963. PubMed ID: 34375349
[TBL] [Abstract][Full Text] [Related]
13. The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions.
Svirskis D; Lin SW; Brown H; Sangaroomthong A; Shin D; Wang Z; Xu H; Dean R; Vareed P; Jensen M; Wu Z
Int J Pharm Compd; 2018; 22(2):164-171. PubMed ID: 29877863
[TBL] [Abstract][Full Text] [Related]
14. Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure.
Shah M; Sandler L; Rai V; Sharma C; Raghavan L
World J Gastroenterol; 2013 Sep; 19(34):5645-50. PubMed ID: 24039356
[TBL] [Abstract][Full Text] [Related]
15. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
Pabari RM; McDermott C; Barlow J; Ramtoola Z
Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
[TBL] [Abstract][Full Text] [Related]
16. Extemporaneous Compounding of Low-strength Aspirin Capsules for Desensitization Protocols.
Messenger C; Soper B; Cutaia K; Zhao F
Int J Pharm Compd; 2024; 28(1):82-86. PubMed ID: 38306624
[TBL] [Abstract][Full Text] [Related]
17. Formulation and stability of diazepam suspension compounded from tablets.
Strom JG; Kalu AU
Am J Hosp Pharm; 1986 Jun; 43(6):1489-91. PubMed ID: 3728485
[TBL] [Abstract][Full Text] [Related]
18. Drug content on receipt and over time for compounded formulations of famciclovir.
Johnson LR; Weaver PG; Forsythe LE; Thomasy SM; Knych HK
J Feline Med Surg; 2021 Jun; 23(6):519-525. PubMed ID: 33019848
[TBL] [Abstract][Full Text] [Related]
19. Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide.
Burton JH; Knych HK; Stanley SD; Rebhun RB
Vet Comp Oncol; 2017 Dec; 15(4):1558-1563. PubMed ID: 28120478
[TBL] [Abstract][Full Text] [Related]
20. A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers.
Bladh N; Blychert E; Johansson K; Backlund A; Lundin C; Niazi M; Pettersson G; Fjellman M
Clin Ther; 2007 Apr; 29(4):640-9. PubMed ID: 17617287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
